Evidence map›Paper›PMID 41074985›Full record

ReviewMolecular biology reports2025

Nanoparticle-driven CRISPR-Cas9 genome editing: a new frontier in crop improvement.

Isha Gupta, Jai Gopal Sharma, Tanushri Kaul

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Isha GuptaDepartment of Biotechnology, Delhi Technological University, Shahbad Daulatpur, Bawana Road, Delhi, India.ORCID http://orcid.org/0000-0001-6949-8925
Jai Gopal SharmaDepartment of Biotechnology, Delhi Technological University, Shahbad Daulatpur, Bawana Road, Delhi, India. sharmajaigopal@yahoo.com.ORCID http://orcid.org/0000-0002-5269-4310
Tanushri KaulNutritional Improvement of Crops Group, Plant Biology & Biotechnology, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India. tanushri@icgeb.res.in.ORCID http://orcid.org/0000-0003-3943-8408

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The agricultural sector has experienced unpredictable and extreme climatic aberrations, which have severely hampered food production. However, applying advanced nanotechnological approaches in agriculture will be crucial for ensuring more secure and sustainable food production. The revolutionizing phyto-nanotechnology enables the precise delivery of biomolecules i.e., nucleotides and proteins, and the modulated release of agrochemicals, including fungicides and pesticides. In addition, CRISPR-Cas-based genetic engineering holds great promise for food security, agriculture, and environmental sustainability. However, its application in plants faces challenges, including cargo delivery, germline transformation, species independence, HDR efficiency, and overall editing effectiveness. Nanomaterials offer innovative and effective solutions to overcome these challenges by enhancing genome-editing tools precision, efficiency, and delivery mechanisms. This review examines the key limitations of CRISPR-mediated plant genome editing and how nanoparticle technologies can overcome them. We highlight essential nanotech innovations that enhance genome modification, paving the way for a faster, more versatile genomic toolbox in plant biotechnology.

Indexed as

CRISPR-Cas SystemsCrops, AgriculturalGene EditingNanoparticlesAgricultureGenetic EngineeringGenome, PlantNanotechnologyPlants, Genetically ModifiedCRISPR-CasGenetic EngineeringGenome Editing (GE)Nanomaterials (NMs)Phyto-nanotechnology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.